Why the study?
Does spironolactone reduce proteinuria in diabetic patients already on ACE inhibitor or ARB therapy?
Does spironolactone reduce proteinuria in diabetic patients already on ACE inhibitor or ARB therapy?
Adding spironolactone to ACEI/ARB therapy in diabetic patients with proteinuria further reduces proteinuria and systolic BP, but requires monitoring for reduced GFR and hyperkalemia.
No takes yet. Share an insight, caveat, or question.
Supports adding modest-dose spironolactone to ACEI/ARB in diabetic proteinuria; extends evidence for further BP and protein reduction with GFR and potassium monitoring.
Saklayen et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: